Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Capital Crunch Starting To Ease For Cancer Immunotherapy Space

Executive Summary

A year later, biotech companies with cancer immunotherapies are beginning to reap the capital rewards of FDA's April 2010 approval of Dendreon's Provenge (sipuleucel-T) for prostate cancer.
Advertisement

Related Content

Potential Universal Cancer Vaccine Will Start Clinical Trials In Ovarian Cancer
Potential Universal Cancer Vaccine Will Start Clinical Trials In Ovarian Cancer
Oncothyreon Looks To Leave Merck KGaA's Shadow With Two Cancer Candidates
Antigen Express Takes Independence For A Spin, Hopes To Move Cancer Vaccine Forward
Selected Financings For Active Cancer Vaccine Developers Since May 1, 2010
RXi Acquires Apthera, Reorganizes To Support Late-Stage Breast Cancer Product
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal
Myeloma Foundation Uses Patient Connections To Help Speed Drug Trials
Venture Philanthropy: The New Venture Capital?

Topics

Advertisement
UsernamePublicRestriction

Register

PS053301

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel